Human cytomegalovirus (HCMV) is among the most important opportunistic pathogens encountered in patients with AIDS. For example, HCMV infection is among the most common cause of oral diseases associated with HIV-positive individuals. Blocking viral lytic replication systemically as well as locally in the infected tissues is central for the treatment of HCMV systemic infections as well as viral-associated oral diseases. The emergence of drug-resistant HCMV strains has posed a need to develop new drugs and novel strategies to combat HCMV infections. The goal of the proposed research is to develop small novel RNA molecules as anti-HCMV therapeutic agents by directing endogenous RNase P to hydrolyze a HCMV essential mRNA and inhibit viral gene expression and replication. These RNA molecules, termed as external guide sequences (EGS), consist of a sequence antisense to the target mRNA and a sequence that guides RNase P to cleave the target. Previous studies have shown that custom-designed EGSs can target both cellular and viral mRNAs for RNase P degradation and inhibit their expression in tissue culture. However, the mechanism of how EGSs interact with the mRNA substrates and RNase P to achieve efficient and specific cleavage has not been extensively studied. Currently it is unknown whether the EGS technology is also effective in modulating gene expression in animal models in vivo. Equally unclear is the specificity and antiviral activity of EGSs in clinically relevant human cells. To address these issues, we propose to generate highly active and sequence-specific EGSs that direct RNase P to cleave the mRNAs encoding viral essential capsid scaffolding protein and UL79. Initially, how the generated EGS RNAs efficiently and specifically induce RNase P for cleavage will be studied in vitro by biochemical approaches. Then, whether these EGSs effectively abolish HCMV replication in human fibroblasts and cells differentiated from CD34+ progenitor cells will be determined, and the effects of the expression of EGSs on the proliferation and differentiation of these cells will be investigated. Moreover, the selected EGSs will be used as a gene targeting tool to investigate the function roles of UL79 in HCMV replication. Finally, using murine CMV infection of mice as the model system, we will determine whether EGSs are effective in blocking viral infection and pathogenesis in vivo in animals. The proposed study will generate novel and exciting EGSs that can serve as lead compounds for anti-HCMV therapeutic development. Furthermore, our study will provide the first direct evidence of whether the EGS-based technology is effective in modulating gene expression in vivo in animals. These results will facilitate the development of these novel RNA-based agents for treatment and studies of AIDS-associated opportunistic infections, including those caused by HCMV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
5R01DE014842-10
Application #
7848269
Study Section
Special Emphasis Panel (ZRG1-AARR-D (03))
Program Officer
Rodriguez-Chavez, Isaac R
Project Start
1999-09-15
Project End
2012-06-30
Budget Start
2010-07-01
Budget End
2012-06-30
Support Year
10
Fiscal Year
2010
Total Cost
$324,810
Indirect Cost
Name
University of California Berkeley
Department
Type
Schools of Public Health
DUNS #
124726725
City
Berkeley
State
CA
Country
United States
Zip Code
94704
Pei, Zenglin; Jiang, Xiaohong; Yang, Zhu et al. (2015) Oral Delivery of a Novel Attenuated Salmonella Vaccine Expressing Influenza A Virus Proteins Protects Mice against H5N1 and H1N1 Viral Infection. PLoS One 10:e0129276
Jiang, Xiaohong; Sunkara, Naresh; Lu, Sangwei et al. (2014) Directing RNase P-mediated cleavage of target mRNAs by engineered external guide sequences in cultured cells. Methods Mol Biol 1103:45-56
Zhang, Tianfu; Yu, Jianxiong; Zhang, Yaqin et al. (2014) Salmonella enterica serovar enteritidis modulates intestinal epithelial miR-128 levels to decrease macrophage recruitment via macrophage colony-stimulating factor. J Infect Dis 209:2000-11
Yang, Zhu; Vu, Gia-Phong; Qian, Hua et al. (2014) Engineered RNase P ribozymes effectively inhibit human cytomegalovirus gene expression and replication. Viruses 6:2376-91
Zhang, Zhigang; Vu, Gia-Phong; Gong, Hao et al. (2013) Engineered external guide sequences are highly effective in inhibiting gene expression and replication of hepatitis B virus in cultured cells. PLoS One 8:e65268
Zeng, Wenbo; Vu, Gia-Phong; Bai, Yong et al. (2013) RNase P-associated external guide sequence effectively reduces the expression of human CC-chemokine receptor 5 and inhibits the infection of human immunodeficiency virus 1. Biomed Res Int 2013:509714
Yang, Zhu; Mao, Guoliang; Liu, Yujun et al. (2013) Detection of the pandemic H1N1/2009 influenza A virus by a highly sensitive quantitative real-time reverse-transcription polymerase chain reaction assay. Virol Sin 28:24-35
Xia, Chuan; Chen, Yuan-Chuan; Gong, Hao et al. (2013) Inhibition of hepatitis B virus gene expression and replication by ribonuclease P. Mol Ther 21:995-1003
Yang, Zhu; Lu, Songya; Xian, Jianchun et al. (2013) Complete genome sequence of a human enterovirus 71 strain isolated in wuhan, china, in 2010. Genome Announc 1:
Zeng, Wenbo; Chen, Yuan-Chuan; Bai, Yong et al. (2012) Effective inhibition of human immunodeficiency virus 1 replication by engineered RNase P ribozyme. PLoS One 7:e51855

Showing the most recent 10 out of 26 publications